US Bioservices now dispenses COPIKTRA

September 27, 2018

The U.S. Food and Drug Administration recently approved COPIKTRA™ (duvelisib) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior therapies.